Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Start Date
6/16/2025
Completion Date
5/1/2026
Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Detailed Description
This study will be for patients in the office having a Nexplanon (etonogestrel implant) insertion. The doctor in clinic will evaluate if a patient meets eligibility criteria for this study. If the patient meets eligibility criteria, the doctor will inform the patient of the study and the potential risks. If patients elect to participate, a research coordinator will obtain written informed consent. The patient will be randomized (patient is blinded) to receive either Pain Ease vapocoolant spray or placebo (normal saline) spray. They will receive the spray just before lidocaine injection during the Nexplanon insertion procedure. The purpose of the study is to see if Pain Ease vapocoolant spray reduces patient pain during lidocaine injection for Nexplanon insertion.
Eligibility Criteria
Age Range: 14 years to No maximum
Interventions
Vapocoolant spray
Placebo
Conditions
Locations
Queens Medical Center POB 2 Suite 402
Honolulu, Hawaii 96813
United States
Queens Medical Center POB1 Clinic 1004
Honolulu, Hawaii 96813
United States
Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120
Waimea, Hawaii 96743
United States